COVID-19 pandemic-associated chilblains: more links for SARS-CoV-2 and less evidence for high interferon type I systemic response

Br J Dermatol. 2022 Dec;187(6):1032-1035. doi: 10.1111/bjd.21820. Epub 2022 Sep 1.

Authors

Didier Bessis^{1

2}, Sophie Trouillet-Assant, Léo-Paul Secco¹, Nathalie Bardin, Brigitte Blanc, Véronique Blatière¹, Christine Chable-Bessia, Christophe Delfour, Céline Girard^{1

2}, Jean-Christophe Richard, Nathalie Gros, Vincent Le Moing, Nicolas Molinari, Valérie Pallure, Amandine Pisoni, Nadia Raison-Peyron¹, Elisa Reynaud, Émilie Schwob¹, Rémi Pescarmona, Quentin Samaran¹, Marjolaine Willems, Thierry Vincent, Mircea T Sofonea, Alexandre Belot, Édouard Tuaillon²

Affiliations

¹ Department of Dermatology, Saint-Eloi Hospital, Competence Centre for Rare Skin Diseases and University of Montpellier, Montpellier, France.
² INSERM U1058, Montpellier, France.

No abstract available

Publication types

Letter

MeSH terms

COVID-19*
Chilblains* / diagnosis
Chilblains* / epidemiology
Chilblains* / etiology
Humans
Interferon Type I*
Pandemics
SARS-CoV-2

Substances

Interferon Type I